Objectives/Hypothesis: Reconstruction of craniofacial cartilagenous defects are among the most challenging surgical procedures in facial plastic surgery. Bioengineered craniofacial cartilage holds immense potential to surpass current reconstructive options, but limitations to clinical translation exist. We endeavored to determine the viability of utilizing adiposederived stem cell-chondrocyte co-culture and three-dimensional (3D) printing to produce 3D bioscaffolds for cartilage tissue engineering. We describe a feasibility study revealing a novel approach for cartilage tissue engineering with in vitro and in vivo animal data.
INTRODUCTION
Reconstruction of craniofacial cartilagenous defects, performed for an unsalvageable auricular or nasal framework in the setting of trauma, oncologic resection, or congenital malformation, is among the most technically challenging surgical endeavors in facial plastic surgery. 1 A select number of surgeons have mastered the art of using autologous rib cartilage, the current gold standard, to carve a neo-framework, resulting in aesthetically and functionally acceptable results. 2, 3 Alternately, some surgeons have elected to use synthetic constructs fashioned in the shape of an auricle or nose.
The field of cartilage tissue engineering (CTE) holds immense potential for creation of bioengineered craniofacial cartilage that both surpasses current reconstructive options and decreases patient morbidity. Several promising studies have demonstrated the use of chondrocytes or chondrogenically pulsed mesenchymal stem cells (MSCs) to produce neocartilage that is histologically and mechanically comparable to native auricular cartilage. [6] [7] [8] [9] These techniques can be combined with patient-specific computer-aided design (CAD) and three-dimensional (3D) printing to produce high-fidelity auricular and nasal tissue engineering scaffolds. 10 However, with the many positive prospects in CTE, significant challenges remain, most notably the need for a large (10 7 ) number of cells. Co-culture, for which chondrocytes and MSCs are simultaneously seeded onto tissue engineering scaffolds, is a new technique that holds promise for circumventing some of the current limitations of utilizing chondrocytes or MSCs alone. Here, we report the use of a co-culture model using adipose-derived stem cells (ASCs) and chondrocytes for CTE. We hypothesize that co-culture technique can be adapted for craniofacial cartilage applications using hydrogels combined with 3D-printed bioresorbable scaffolds and that a variety of ratios of ASCs to chondrocytes may be utilized. This approach affords the potential for patientspecific CTE using CAD while mitigating the limitations of cell availability and need for prolonged in vitro cell culture or exogenous growth factor exposure of traditional CTE approaches. These represent key barriers to the eventual goal of creating a clinically translatable patient-specific craniofacial CTE methodology. Our objective is to assess the feasibility of this approach and the effect of ASC-tochondrocyte ratio on cartilage production using histologic, immunohistochemical, and biochemical analysis.
MATERIALS AND METHODS
Protocol approval was obtained by the University of Michigan Institutional Animal Care and Use Committee (#3857) and the University of Illinois Institutional Animal Care and Use Committee (#10114) .
Scaffold Design and Manufacturing via 3D Printing
Scaffolds were created using previously described imagebased hierarchical design methods developed by Hollister et al. [11] [12] [13] [14] [15] [16] [17] This process can be used to create patient-specific tissue engineering scaffolds of any geometry. 10 A standard 10-mm 3 5-mm cylindrical disc scaffold macroarchitecture with a 2.7-mm spherical pore internal microarchitecture was chosen for this study to produce consistency of constructs for tissue analysis (Fig. 1A) . This yielded an overall scaffold porosity of 68.3% with an available volume per scaffold of 268 lL. A midline groove was incorporated into the scaffold to facilitate bifurcation during analysis. The final scaffold design was then 3D-printed using an EOS P100 laser sintering system (EOS North America, Novi, MI) adapted to laser sinter L-polycaprolactone (PCL) powder (PCL source: Polysciences, Warrington, PA; PCL preparation: Jet Pulverizer, Moorsetown, NJ). 18 The lasersintering process can accurately reproduce feature sizes on the order of 700 lm and produce over 500 representative scaffolds with a single print cycle (Fig. 1B) . Scaffolds were cleaned of residual excess powder via sonication in 70% sterile ethanol, then sterilized in a 24-hour 70% sterile ethanol soak prior to use.
Cell Harvest and Culture
Porcine ASCs derived from subcutaneous back fat and chondrocytes derived from auricular and tracheal cartilage were harvested from adolescent Yorkshire pigs using previously developed methods. 19, 20 Porcine cells were utilized for experiments due to the investigators' experience with these cells and availability of the necessary cell types. Primary (P)0 ASC and chondrocyte cells were spun down and frozen prior to cell seeding experiments. At the time of preparation for scaffold seeding, cells were thawed and expanded in growth media consisting of high-glucose Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Thermo Fischer Scientific, Waltham, MA) with 10% fetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin, and 0.2% Fungizone (Gibco, Thermo Fischer Scientific, Waltham, MA) in a 37 8C, 5% CO 2 incubator. Adipose-derived stem cells were expanded to passage 2 (P2), and chondrocytes were expanded to passage 1 (P1), to provide sufficient cells for seeding. Cells were passaged at 90% confluence. 
Creation of Experimental Ratios and Scaffold Seeding
Adipose-derived stem cells and chondrocytes were rinsed with Hank's buffered saline solution (HBSS) (Gibco, Thermo Fischer Scientific, Waltham, MA), trypsinized (0.25% trypsin) (Gibco, Thermo Fischer Scientific, Waltham, MA), and aliquoted into experimental ASC-to-chondrocyte ratios of 1:1, 2:1, 5:1, 10:1, and 0:1. Cell counting was performed prior to cell mixing using an automated cell counter (Moxi Z, Orflo Technologies, Ketchum, ID). Given that the cells were harvested from several animals, each cell type was pooled prior to creation of experimental ratios. Each experimental group was then re-suspended in a type I collagen:hyaluronic acid hydrogel solution and seeded into a pre-wetted cylindrical PCL scaffold. 21 The hydrogel consisted of type I collagen at a concentration of 6 mg/mL in acetic acid (Discovery Labware, Ketchum, ID) and hyaluronic acid at a concentration of 3 mg/mL (LifeCore Biomedical, Chaska, MN). Prior to seeding, the PCL scaffolds were placed in custom-fabricated silicone (Sylgard, Dow Corning, Midland, MI) molds to prevent extravasation of the seeding solution prior to gelation. A 0.05N NaOH in NaCO 3 solution was used to induce gelation, and scaffolds were subsequently transferred to 24-well low attachment plates (Fischer Scientific) for culture. The cell seeding density was 2 3 10 6 cells/cm 3 , and a total of 12 scaffolds per experimental group were seeded.
In Vitro Incubation
Seeded constructs were placed individually within a 24-well low attachment plate with one scaffold per well and placed in a sterile CO 2 incubator. Scaffolds were incubated at 37 8C with 5% CO 2 on an orbital shaker within the incubator for 4 weeks. Culture media was changed every 2 to 3 days by aspirating old media from each culture well and then replacing it with 1.25 mL of fresh media warmed to 37 8C within a sterile culture hood. Culture media consisted of low-glucose DMEM with 10% FBS, 1% penicillin-streptomycin (Gibco, Thermo Fischer Scientific, Waltham, MA), and 0.2% Fungizone. After 4 weeks, six scaffolds from each experimental group were extracted for postin vitro biochemical analysis, whereas the remaining six were reserved for in vivo implantation.
In Vivo Implantation
Seven athymic rats underwent implantation with tissue engineering scaffolds under general anesthesia with isoflurane delivered by mask. All scaffolds were rinsed with HBSS prior to implantation. All animals were male, with each weighing between 250 and 305 g. Each animal was shaved, prepped with iodine solution after induction of anesthesia, and then a vertical incision was sharply made on the dorsum of the animal. A total of four scaffolds per animal were implanted in a subcutaneous pocket into randomized quadrants on the back of the animal. The incision was then closed with surgical staples, which were removed on postoperative day 7. After 4 weeks, the animals were euthanized, and the scaffolds were harvested for post-in vivo analysis.
Biochemical Analysis
Post-in vitro and post-in vivo specimens were split along the midline groove to double the number of constructs for analysis. One-half of each construct was weighed wet, lyophilized, reweighed dry, and digested in 1 mg/mL Papain stock solution (Fischer Scientific) at 65 8C for 16 hours. PicoGreen assay (Invitrogen, Molecular Probes, Carlsbad, CA) was used to quantify the DNA content of the constructs with Lambda phage DNA (0-1 mg/ mL) as a standard. The sulfated-glycosaminoglycan (s-GAG) content was measured using the Blyscan Glycosaminoglycan Assay (Accurate Chemical & Scientific Corp., Westbury, NY).
Histology and Immunhistochemistry
The remaining post-in vivo constructs were fixed in 4% formalin for 24 hours, embedded in paraffin (TissuePrep, Fischer Scientific), and processed using standard histologic procedures with a slice thickness of 10 lm. Stains included hematoxylin and eosin, Safrinin-O, and toluidine blue (Gibco, Thermo Fischer Scientific, Waltham, MA). Type II collagen immunohistochemical staining was performed using 5 lg/mL primary mouse anti-type II collagen monoclonal antibodies (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA).
Statistical Analysis
Data for biochemical analysis (DNA and s-GAG expression) were collected from six samples per co-culture experimental group after 4 weeks of in vitro cell culture and 4 weeks of in vivo growth. Data was expressed as mean 6 standard error of the mean. Results were analyzed using Student t test with SPSS 17.0 (SPSS Inc., Chicago, IL), and statistical significance was set to 5% (a 5 0.05) in all analyses.
RESULTS
In vitro co-culture of porcine ASCs and chondrocytes in 3D-printed PCL cylindrical discs with an internal spherical porous architecture resulted in growth and maintenance of cartilage-like tissue after 8 weeks (4 weeks in vitro plus 4 weeks in vivo). Surgical implantation was straightforward, and the scaffolds were well tolerated by the animals with no minor or major complications. There was good maintenance of structural support by the PCL scaffolds after 4 weeks growth in a subcutaneous pocket, as shown in Figure 1C . Histologically normal-appearing cartilage growth was noted in all experimental co-culture groups after 1 month of in vivo culture, which was confirmed with type II collagen immunohistochemistry (Fig. 2) . Notably, the 5:1 ASC-tochondrocyte ratio demonstrated well delineated hyaline cartilage architecture in histology, with dense collagen deposition and lacunae surrounding the chondrocytes and differentiated ASCs within the microspheres of the scaffold (Figs. (3 and 4) ) Biochemical analysis results are summarized in Figure 5 . There was no statistically significant difference in s-GAG content normalized to scaffold wet weight (lg/mg) or DNA content (lg/mg) between the co-culture experimental groups at the post-in vitro or post-in vivo time points. There was a statistically significant higher s-GAG content normalized to scaffold wet weight (lg/mg) and DNA content (lg/mg) in all co-culture groups compared to the chondrocyte-alone control group (P < 0.05 for all analyses) at the post-in vitro timepoint; however, this difference disappeared at the post-in vivo timepoint.
DISCUSSION
Reconstruction of the auricular and external nasal frameworks, whether performed in the setting of trauma, oncologic resection, or congenital malformation, are some of the most demanding procedures in facial reconstructive surgery. Few surgeons have mastered the art of using autogenous rib cartilage, the current gold standard, to carve a neo-auricular framework resulting in aesthetically pleasing results. 2, 3 Moreover, this approach typically requires multiple revision procedures and carries risks of donor site morbidity, pneumothorax, undesired scarring, and graft failure or infection. Alternately, some surgeons elect to use synthetic porous highdensity polyethylene (MedPor, Styker Corporation, Kalamazoo, MI) for reconstruction. 4 This rigid, synthetic material can be fashioned into a neo-auricular framework for subcutaneous implantation. However, rates of necrosis of the overlying skin and framework extrusion, although poorly reported, occur in at least 3% to 5% of cases. 4 Tissue engineering holds several ubiquitous advantages, including the ability to create a patient-specific living construct using the patient's own cells. Several promising studies have demonstrated the use of chondrocytes or MSCs cultured in prochondrogenic growth factors (GFs) as being able to develop neocartilage that is histologically and mechanically similar to native ear cartilage. [6] [7] [8] [9] In these models, chondrocytes or MSCs are harvested, passaged, and expanded-and then seeded onto a scaffold and cultured in vitro prior to subcutaneous implantation. A variety of scaffold materials, including polyglycolic acid, polycaprolactone, chitosan, and silk, have been used successfully with varying properties that are favorable for different conditions. [6] [7] [8] [9] However, with the many positive prospects of producing a tissueengineered auricle, new challenges have also surfaced.
The primary limitation of utilizing solely chondrocytes for CTE is the large number of cells (up to 5 3 10 7 ) needed to seed human-sized craniofacial frameworks. 9, [22] [23] [24] [25] [26] The number of chondrocytes available from autologous cartilage is limited, and passaging chondrocytes induces dedifferentiation with loss of type II collagen and s-GAG production. 27 Mesenchymal stem cells, of which ample cell quantities are available, have been posited as a solution to seeding requirements. Prior experiments have shown a variety of MSC types, including ASCs and bone-marrow stromal cells, to be capable of chondrogenic differentiation. 28, 29 However, chondrogenic commitment of MSCs requires exogenous delivery of GFs for weeks and cells can demonstrate a propensity for ossification. 30, 31 Additionally, neovascularization of 3D tissue-engineered cartilagenous constructs has proven to be a challenge to the long-term stability of these constructs, particularly with fragility of ASCs in hypoxic tissue environments. 32 Co-culturing of chondrocytes and MSCs is a new technique that holds promise for circumventing some limitations of utilizing chrondrocytes or MSCs alone. In a co-culture model, chondrocytes and MSCs are simultaneously seeded onto a tissue engineering scaffold. Chondrocytes have been found to induce chondrogenic differentiation of the MSCs via production of exogenous GFs such as cytokine-like protein 1 (Cytl1), bone morphogenic protein-2 (BMP-2), parathyroid hormonerelated peptide (PTHrP), and transforming growth factor-beta (TGF-b)-as well as paracrine, juxtacrine, and gap-junction signaling pathways. [33] [34] [35] [36] In this way, chondrocytes maintain the chondrogenic niche required for commitment of MSCs to the chondrogenic phenotype, circumventing the need for exogenous GF delivery. Additionally, chondrocytes provide matrix for MSC migration and prevent ossification of MSC-derived chondrocytes. 37 Our group has previously developed a process utilizing image-based design and 3D printing to produce highfidelity, patient-specific tissue engineering scaffolds using PCL, a bioresorbable polymer. 10 Utilization of a bioresorbable material allows for eventual replacement of the scaffold with chondrocyte extracellular matrix, thus best emulating natural craniofacial cartilage. We have previously seeded these scaffolds with primary chondrocytes to produce tissue-engineered auricular and nasal constructions. 10 One advantage of a scaffold-specific CAD approach utilizing 3D-printed biomaterials is the ability to generate an intra-scaffold environment more conducive to cell survival and neovascularization. Our group has previously performed studies, demonstrating that a spherical pore microarchitecture results in improved cell survival and cartilage deposition for CTE. 38 This process affords the ability to rapidly chondrogenically while also allowing meticulous control of the pore microarchitecture. However, our prior investigations have been limited by many of the previously described constraints, including the limited number of chondrocytes available for harvest, the need to passage chondrocytes in cell culture, and the need for prolonged exogenous GF exposure.
Although other studies have utilized ASC/chondrocyte co-culture for CTE, 39 this report is the first to our knowledge describing successful use of ASC co-culture on 3D-printed tissue engineering scaffolds for successful CTE. The use of ASCs with a co-culture technique is particularly advantageous for a clinically translatable approach given the low morbidity to harvest these cells vis-a-vis bone-marrow derived stromal cells. The described process can readily be adapted for tissue engineering constructs of any shape, including patientspecific auricular and nasal constructs using digital imaging and communications in medicine (DICOM) data (Fig. 6) . 10 Our results demonstrate that all the experimental ratios of ASC to chondrocytes in our study resulted in type II collagen and cartilage production on short-term in vivo analysis. Notably, this was achieved without the use of exogenous GFs during scaffold incubation. Using a cell count goal of 5 3 10 7 as the number of cells needed for a typical human-sized auricle, ratios of 10:1 and 5:1 ASC: primary chondrocytes (PC) yield cell number requirements that are clinically achievable from a cell harvest without the need for prolonged passaging of cells in the laboratory setting. 40 These represent important barriers to a clinically translatable process for craniofacial CTE, which appear to be overcome with a co-culture technique.
Interestingly, the co-culture scaffold groups all appeared to perform similarly, despite the different ratios of ASC to chondrocytes. Additionally, the coculture groups appeared to outperform the chondrocytealone scaffolds in amount of histologic cartilage deposition, despite identical cell seeding densities. This may represent an inherent superior viability of co-cultured cells in this methodology or synergistic interaction of cocultured cells to promote chondrogenesis. However, this could also be an artifact of decreased viability of chondrocytes in cell culture. Given that no analysis of cell viability or gene expression was performed in this study, these ideas remain speculative.
Our feasibility study is limited by a short in vivo incubation period and small number of constructs. As such, statistical differences of the biochemical characteristics of the experimental groups may have not been captured, or differences in the trajectory of tissue deposition with more prolonged in vivo growth. Inferences regarding human translatability of a tissue engineering model utilizing porcine cells should be tempered until similar results can be demonstrated using human-derived PCs and ASCs. Our PCL constructs are anticipated to maintain construct fidelity for 2 to 3 years prior to resorption. More prolonged in vivo study will be necessary to determine whether the tissue-engineered construct contracts or resorbs after scaffold dissolution. Additional study of the microscopic orientation and mechanical characteristics of ASC:PC co-cultured constructs will help delineate whether co-cultured cartilage creates primarily elastic cartilage or fibrocartilage, although this is of less importance in a structure such as an auricle. Further cell viability and gene expression analysis studies would also help characterize the chondrogenic commitment of ASCs and the ability of ASCs and PCs to tolerate co-culture on 3D-printed bioscaffolds. We chose an incubation period of 4 weeks for our scaffolds after cell seeding in concordance with previously described CTE techniques. However, given the lack of a need for exogenous GF delivery with a co-culture approach, we are currently investigating a "seed-and-go" approach in which scaffolds are implanted immediately after cell seeding. Given that our MSCs were not immunofluorescently labeled, direct demonstration of chondrogenic differentiation of the MSCs was not possible. Nor was it possible to assess migration of host MSCs into the constructs. However, we feel that histologic markers are a sufficient surrogate in the scope of this experiment given prior work, which has demonstrated the successful chondrogenic commitment of MSCs using this technique.
CONCLUSION
We confirm the successful use of an ASC-chondrocyte co-culture technique and CAD-designed 3D-printed tissue engineering scaffolds for CTE in an animal model. This co-culture model produced formal cartilage production on short-term in vivo follow-up in all experimental groups, including ASC-to-chondrocyte ratios of 5:1 and 10:1. The clinical availability of ASCs and lack of a need for prolonged exogenous GF exposure suggest that this approach mitigates many of the limitations of traditional CTE approaches. These represent key barriers to the eventual goal of creating a clinically translatable patient-specific craniofacial CTE methodology that may be overcome using co-culture and 3D printing. 
